BETABiohacksAI is a research tool for informational purposes only. All outputs are computational hypothesis candidates — not confirmed mechanisms, not medical advice, and not a substitute for professional medical judgment. Independent experimental validation is always required.
BiohacksAI is an evolving scientific literature platform. New compounds and evidence are indexed continuously.
B
○

Rilmenidine

an agonist for ALPHA-2 ADRENERGIC RECEPTORS and IMIDAZOLINE RECEPTORS. It is used in the treatment of HYPERTENSION.

300+ PubMed studies analyzed · 24 RCTs · Evidence Score: 43.4

Research Domains

Rilmenidine has been studied across 19 research domains including ❤️ Cardiovascular, 🫘 Kidney, 🧠 Focus & Attention, 🔥 Metabolic, ⏳ Longevity & Aging. The primary research focus is ❤️ Cardiovascular with 57% of studies addressing this area.

Similar Compounds by Shared Targets

The following compounds share molecular targets with Rilmenidine, based on binding affinity data from BindingDB and ChEMBL. Sorted by shared target overlap.

Guanfacine
9 shared targets
biphenyline
4 shared targets
cirazoline
4 shared targets
Naphazoline
6 shared targets
moxonidine
3 shared targets
selegiline
4 shared targets
brimonidine
4 shared targets
corynantheine
4 shared targets
Piperoxan
4 shared targets
Methoxamine
4 shared targets
Loading evidence profile...

This evidence profile for Rilmenidine is generated deterministically from 300 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.

Data source: PubMed/MEDLINE (NLM). Corpus version: current. Patent pending (EVE-PAT-2026-001). © 2026 Organiq Sweden AB.